Investigational Drug Information for PTI-801
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
What is the drug development status for PTI-801?
PTI-801 is an investigational drug.
There have been 29 clinical trials for PTI-801.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 14th 2017.
The most common disease conditions in clinical trials are Alzheimer Disease, Cystic Fibrosis, and Fibrosis. The leading clinical trial sponsors are Pain Therapeutics, Proteostasis Therapeutics, Inc., and Cassava Sciences, Inc.
There is one US patent protecting this investigational drug and twenty international patents.
Summary for PTI-801
| US Patents | 1 |
| International Patents | 20 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2017-11-14) |
| Vendors | 3 |
Recent Clinical Trials for PTI-801
| Title | Sponsor | Phase |
|---|---|---|
| Open-label Extension for Phase 3 Clinical Trials of Simufilam | Cassava Sciences, Inc. | Phase 3 |
| Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease | Cassava Sciences, Inc. | Phase 2 |
| Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease | Premier Research International LLC | Phase 3 |
Clinical Trial Summary for PTI-801
Top disease conditions for PTI-801
Top clinical trial sponsors for PTI-801
US Patents for PTI-801
International Patents for PTI-801
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PTI-801 | Argentina | AR106279 | 2035-10-06 | ⤷ Sign Up |
| PTI-801 | Australia | AU2016336437 | 2035-10-06 | ⤷ Sign Up |
| PTI-801 | Australia | AU2020233776 | 2035-10-06 | ⤷ Sign Up |
| PTI-801 | Brazil | BR112018007021 | 2035-10-06 | ⤷ Sign Up |
| PTI-801 | Canada | CA3000483 | 2035-10-06 | ⤷ Sign Up |
| PTI-801 | China | CN108430994 | 2035-10-06 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
